Fore Biotherapeutics

A precision oncology company rooted in science and innovation, pioneering the development of unique cancer therapies.

[Fore Biotherapeutics @ForeBiotx]

We’re on the ground in New York at the Jefferies 2026 Global Healthcare Conference.

To request a meeting with management, please reach out to [email protected]

#ForeBio

[Fore Biotherapeutics @ForeBiotx]

We are at #ASCO26 connecting with colleagues, partners, and the broader oncology community. Connect with #ForeBio at Booth #35103 to learn about plixorafenib.

[Fore Biotherapeutics @ForeBiotx]

Fore Bio will participate in the Stifel 2026 Virtual Targeted Oncology Forum on May 19 and Jefferies 2026 Global Healthcare Conference on June 2. To request a meeting with management, please contact Argot Partners ([email protected]).

Learn more: https://t.co/3B76DIU13c

[Fore Biotherapeutics @ForeBiotx]

We’re proud that the FDA has recently granted BTD to plixorafenib for the treatment of adult patients with #HGG. We look forward to continuing collaboration with the FDA to further advance plixorafenib and our FORTE basket trial in several types of BRAF altered malignancies.

[Fore Biotherapeutics @ForeBiotx]

#BreakthroughTherapy Designation granted to plixorafenib for the treatment of #HGG reinforces our commitment to bringing plixorafenib to patients. Thank you to our team and partners who are working towards bringing this treatment to patients as quickly as possible.

[Fore Biotherapeutics @ForeBiotx]

FDA granted Breakthrough Therapy Designation to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma. This recognizes plixorafenib’s potential to provide substantial improvement over available therapies.
Learn more: https://t.co/dMBiLwIPf5

[Fore Biotherapeutics @ForeBiotx]

We look forward to connecting with industry leaders and innovators during #JPM2026.

Please contact Argot Partners ([email protected]) to schedule one-on-one meetings with management.

See you in San Francisco!

[Fore Biotherapeutics @ForeBiotx]

Wishing you a joyful holiday season from all of us at Fore Bio. We’re grateful for the continued support and collaboration that made this year a success. Here's to a healthy and impactful year ahead!

[Fore Biotherapeutics @ForeBiotx]

Our CEO, Bill, recently joined #TheBioCenturyShow. Drawing on his extensive biotech and oncology experience, Bill shares why plixorafenib is uniquely positioned to address critical unmet needs in BRAF-driven tumors. Tune in: https://t.co/kUgpASn6B7

[Fore Biotherapeutics @ForeBiotx]

A sincere thank you to Dr. Eric Sherman for joining our KOL roundtable discussion on plixorafenib, and for providing his insights into its potential role in treating patients with BRAF-driven tumors.

Listen to a replay of the webcast here: https://t.co/9D3KWyT78Z

[Fore Biotherapeutics @ForeBiotx]

A huge thank you to Dr. Macarena de la Fuente for her expertise and insights during our recent KOL roundtable discussion on plixorafenib and its potential to disrupt the BRAF market for the benefit of patients.

Listen to a replay of the webcast here: https://t.co/9D3KWyT78Z

[Fore Biotherapeutics @ForeBiotx]

See you at #SNO2025! Members of the Fore team are headed to @NeuroOnc’s 30th Oncology Annual Meeting in Honolulu, HI.

We look forward to connecting with clinical leaders in neuro-oncology to discuss the potential role of plixorafenib in monotherapy indications.

[Fore Biotherapeutics @ForeBiotx]

Sincere thanks to Dr. Patrick Wen for his invaluable contributions to our recent KOL roundtable discussion on plixorafenib and its potential to disrupt the BRAF market for the benefit of patients.

Listen to a replay of the webcast here: https://t.co/9D3KWySzjr

[Fore Biotherapeutics @ForeBiotx]

Today, Fore Bio announced that management will participate in the following upcoming investor conferences in November. To request a meeting with management, please contact Argot Partners ([email protected]). Learn more: https://t.co/lyGLqE0tdz

[Fore Biotherapeutics @ForeBiotx]

We presented new preclinical plixorafenib data yesterday at AACR-NCI-EORTC 2025 demonstrating tumor growth inhibition in preclinical models of BRAF-mutated primary and brain metastatic melanoma.

Read the abstract: https://t.co/m0Dzlul3sw

#Targets25 #AACR #CancerResearch

[Fore Biotherapeutics @ForeBiotx]

Earlier this month, the Fore team proudly participated in the Race For Hope Greater Philadelphia for a 5K Run hosted by the National Brain Tumor Society (@NBTStweets) to support patients affected by brain tumors and their families.

#Biotech #ForeBio #BrainTumorAwareness

[Fore Biotherapeutics @ForeBiotx]

Thank you to everyone who joined yesterday’s virtual KOL roundtable discussion on plixorafenib with leading oncology experts Macarena de la Fuente, MD, Patrick Wen, MD, and Eric Sherman, MD

A replay of the webcast is available on Fore’s website here: https://t.co/Pk8Z91qQre

[Fore Biotherapeutics @ForeBiotx]

Please join us today at 12pm ET for a KOL roundtable discussion on plixorafenib’s disruptive potential in the evolving BRAF treatment landscape. We are honored to be hosting a panel of 3 renowned key opinion leaders. Register here: https://t.co/cey1aPhJG0

[Fore Biotherapeutics @ForeBiotx]

Join us tomorrow, Wed, Oct 15, at 12pm ET for a virtual roundtable discussion on plixorafenib’s disruptive potential in the BRAF treatment landscape, featuring 3 renowned key opinion leaders.

To register for the event, please click here: https://t.co/cey1aPhJG0

[Fore Biotherapeutics @ForeBiotx]

We’re hosting a virtual roundtable discussion featuring 3 key opinion leaders on Wed, Oct 15, at 12pm ET to discuss plixorafenib’s disruptive potential in the BRAF market.

Learn more about the event here: https://t.co/xSP3OB37Rt

Register here: https://t.co/cey1aPhJG0